However, our in vivo studies with the CRC cell line HCT116 (KRAS G13D) and PDX C1138 (KRAS G13D), both failed to demonstrate improve efficacy of combining MEK and SRC inhibitors. Here, KRAS is linked to colorectal carcinoma.